Navigation Links
Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013
Date:5/6/2009

Current and Emerging Targeted Therapies Such As AstraZeneca's Iressa and Roche's Avastin Will Drive the Market From 2008 to 2013, According to a New Report from Decision Resources

WALTHAM, Mass., May 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in China will more than double by 2013, growing from $307 million in 2008 to $648 million in 2013. This growth will be fueled by a large increase in non-small-cell lung cancer diagnosed incident cases, improvement in access to medical care and significantly increased prescribing of targeted therapies.

"Urbanization and an aging population will result in a 47 percent increase in the number of diagnosed incident cases of non-small-cell lung cancer in China during 2008 to 2018. The most significant increase will occur in urban China, where we expect the number of diagnosed incident cases to increase 72 percent, in contrast to just eight percent in rural regions by the end of the 2018," stated Jing Wu, M.S., MBA.

The new Emerging Markets report entitled Non-Small-Cell Lung Cancer in China also finds that increased penetration of current targeted therapies such as AstraZeneca's Iressa (gefitinib), Roche's Tarceva (erlotinib) and Jiangsu Simcere's Endostar (endostatin) and the launch of new targeted therapies -- Roche's Avastin (bevacizumab) and Merck KGaA's Erbitux (cetuximab) -- are the main driving forces in the Chinese non-small-cell lung cancer market from 2008 to 2013.

"In 2008, sales of non-small-cell lung cancer drugs in China totaled $307 million -- a 13 percent increase from our 2006 report," added Ms. Wu. "In 2008, the increased prescription of Iressa, Tarceva and Endostar was the major factor contributing to this market growth."

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. High alcohol consumption increases stroke risk among Chinese men
2. Heavy Drinking Boosts Stroke Risk for Chinese Men
3. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
4. Chinese takeaway in the Wadden Sea
5. A Chinese medicine compound has satisfactory anti-cancer effects on hepatocellular carcinoma
6. China Shenghuo Pharmaceutical Holdings, Inc. Opens Showcase 12Ways(R) Chinese Herbal Beauty Salon in October
7. CHRI Receives Approval for Suining Chuan DAR Authentication Trademark From Chinese Government
8. All-State Properties, L.P. Announces Termination of Reverse Merger With Chinese Pharmaceutical Company
9. Rh-Apo2L Named as One of Chinas High-Tech Transforming Products by Chinese Government
10. What are the essential characteristics of serum PG in Chinese?
11. Linkwell Chairman & CEO Addresses the Association of Chinese Nosocomial Infections Professional Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that ... dermaka cream can be incorporated into the post-surgical treatment plans of a variety of ... , dermaka cream is very effective for bruising and causes a rapid resolution of ...
(Date:6/24/2016)... IL (PRWEB) , ... June 24, 2016 , ... ... Beard, DDS, and Randall Markarian, DDS, are co-chairs for the Illinois State Dental ... clinic Friday-Saturday, July 15-16 at the Gateway Convention Center in Collinsville. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: